News

Dubbed SAVOIR, the phase 3 trial will be held globally in five to ten countries to assess the efficacy and safety of savolitinib in comparison with sunitinib. The open-label,

The approval has been followed by a recommendation of the Committee for Medicinal Products for Human Use (CHMP) in May. It allows to market the drug in the

The collaboration intends to come up with a solution to address antibiotic resistance, a global health problem that is making treatment of common infectious diseases difficult and at

The safety profile of anacetrapib in the early analysis was generally consistent with that demonstrated in previous studies of the drug, including accumulation of anacetrapib in adipose tissue,

The regulatory body has unveiled a list of off-patent and off-exclusivity branded drugs without approved generics, as well as launched a new policy to speed up the assessment

Mitoconix Bio is pioneering a novel strategy to improve mitochondrial function as a disease-modifying therapeutic for treating neurodegenerative disorders, including Huntington's, Parkinson's and Alzheimer's diseases. Proceeds from the

The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations which the company leases in the

Developed by Novartis’ unit Sandoz, Erelzi has been approved as an alternative option for all indications of the reference drug. Erelzi can be used by physicians to treat rheumatoid

The approval has been granted for Kevzara to treat moderately to severely active RA in adult patients who have responded inadequately or who are intolerant to one or